{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:34:58Z","timestamp":1771014898446,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40258-018-0401-y","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T06:55:07Z","timestamp":1529391307000},"page":"569-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway"],"prefix":"10.1007","volume":"16","author":[{"given":"Fredrik Salvesen","family":"Haukaas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audun","family":"Ohna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Krivasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"issue":"8","key":"401_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14(8):517\u201334. https:\/\/doi.org\/10.1038\/nrc3774 .","journal-title":"Nat Rev Cancer."},{"issue":"9","key":"401_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790\u20135.","journal-title":"Am J Hematol"},{"issue":"9","key":"401_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575\u201384.","journal-title":"Br J Cancer"},{"issue":"6","key":"401_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, De Santis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443\u201359.","journal-title":"CA Cancer J Clin"},{"key":"401_CR5","unstructured":"Cancer Registry of Norway. Cancer in Norway 2015 \u2013 cancer incidence, mortality, survival and prevalence in Norway. Report, Cancer Registry of Norway, Oslo. 2016. https:\/\/www.kreftregisteret.no\/globalassets\/cancer-in-norway\/2015\/cin2015-special_issue-web.pdf . Accessed 12 June 2018."},{"issue":"7","key":"401_CR6","doi-asserted-by":"publisher","first-page":"e0131158","DOI":"10.1371\/journal.pone.0131158","volume":"10","author":"D Barzenje","year":"2015","unstructured":"Barzenje D, Cvancarova Sm\u00e5stuen M, Liest\u00f8l K, Foss\u00e5 A, Delabie J, Kolstad A, Holte H. Radiotherapy compared to other strategies in the treatment of stage I\/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS One. 2015;10(7):e0131158.","journal-title":"PLoS One"},{"key":"401_CR7","unstructured":"NoMA. Hurtig metodevurdering: ID2016_013 Obinutuzumab (Gazyvaro) til behandling av follikul\u00e6rt lymfom som er refrakt\u00e6rt til rituksimab eller rituksimabholdig regime. Vurdering av innsendt dokumentasjon. 2017. https:\/\/nyemetoder.no\/Documents\/Rapporter\/Obinutuzumab%20(%20FL)%20-%20hurtig%20metodevurdering.pdf . Accessed 12 June 2018."},{"key":"401_CR8","unstructured":"Directorate of Health. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne lymfomer. IS-2429, 2016. https:\/\/helsedirektoratet.no\/retningslinjer\/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-maligne-lymfomer . Accessed 12 Mar 2018."},{"issue":"11","key":"401_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3109\/10428194.2011.593270","volume":"52","author":"AH Blaes","year":"2011","unstructured":"Blaes AH, Ma L, Zhang L, Peterson BA. Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52(11):2105\u201310.","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"401_CR10","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"401_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"BS Kahl","year":"2010","unstructured":"Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116(1):106\u201314.","journal-title":"Cancer"},{"issue":"4","key":"401_CR12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"SJ Horning","year":"2005","unstructured":"Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23(4):712\u20139.","journal-title":"J Clin Oncol"},{"issue":"16","key":"401_CR13","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","volume":"119","author":"MS Czuczman","year":"2012","unstructured":"Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698\u2013704.","journal-title":"Blood"},{"key":"401_CR14","unstructured":"EMA. Annex I summary of product characteristics, 2014. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002799\/WC500171594.pdf . Accessed 9 Aug 2017."},{"issue":"8","key":"401_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393.","journal-title":"Lancet Oncol"},{"key":"401_CR16","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"key":"401_CR17","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.V128.22.3605.3605","volume":"128","author":"GF Guzauskas","year":"2016","unstructured":"Guzauskas GF, Masaquel A, Reyes C, et al. What is the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US? Blood. 2016;128:3605.","journal-title":"Blood."},{"key":"401_CR18","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. Report by the decision support unit. 2 June 2017 decision support unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street. Sheffield, S1 4DA, 2017. http:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wp-content\/uploads\/sites\/7\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf . Accessed 05 Mar 2018."},{"key":"401_CR19","unstructured":"NoMA. Retningslinjer for dokumentasjonsgrunnlag for hurtig metodevurdering av legemidler. 2018.\u00a0 https:\/\/legemiddelverket.no\/Documents\/Refusjon%20og%20pris\/Dokumentasjon%20til%20metodevurdering\/Retningslinjer%20for%20dokumentasjonsgrunnlag%20ved%20metodevurdering%2001012018.pdf . Accessed 12 June 2018."},{"key":"401_CR20","doi-asserted-by":"crossref","unstructured":"Cheson et al. 615 Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. Abstract at the American Society of Hematology. 2016. http:\/\/www.bloodjournal.org\/content\/128\/22\/615 . Accessed 12 June 2018.","DOI":"10.1182\/blood.V128.22.615.615"},{"key":"401_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33:743\u201354.","journal-title":"Med Decis Making"},{"key":"401_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hon.2439_115","volume":"35","author":"A Rivas-Delgado","year":"2017","unstructured":"Rivas-Delgado A, Magnano L, Moreno-Velazquez M, Garcia O, Mozas P, Dlouhy I, Baumann T, Rovira J, Gonzalez B, Martinez A, Balague O, Delgado J, Villamor N, Campo E, Gine E, Sancho JM, Lopez-Guillermo A. Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era. Hematol Oncol. 2017;35:360\u20131. https:\/\/doi.org\/10.1002\/hon.2439_115 .","journal-title":"Hematol Oncol"},{"key":"401_CR23","unstructured":"Directorate of Health. Innsatsstyrt finansiering. 2016. https:\/\/helsedirektoratet.no\/Lists\/Publikasjoner\/Attachments\/1119\/Endelig%20ISF-regelverk%202016%20IS-2417.pdf . Accessed 12 June 2018."},{"key":"401_CR24","unstructured":"Towse A, Barnsley P. Clarifying meanings of absolute and proportional shortfall with examples. Office of Health Economics. 2013. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/OHE-Note-on-proportional-versus-absolute-shortfall.pdf . Accessed 12 June 2018."},{"key":"401_CR25","unstructured":"Statistics Norway. D\u00f8delighetstabeller, 2018. https:\/\/www.ssb.no\/befolkning\/statistikker\/dode . Accessed 06 March 2018."},{"issue":"2","key":"401_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1403494811435493","volume":"40","author":"S Sun","year":"2012","unstructured":"Sun S, Irestig R, Burstrom B, Beijer U, Burstrom K. Health-related quality of life (EQ-5D) among homeless persons compared to a general population sample in Stockholm County, 2006. Scand J Public Health. 2012;40(2):115\u201325.","journal-title":"Scand J Public Health"},{"issue":"7","key":"401_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstr\u00f6m","year":"2001","unstructured":"Burstr\u00f6m K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621\u201335.","journal-title":"Qual Life Res"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-018-0401-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0401-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0401-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T15:27:10Z","timestamp":1720366030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-018-0401-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s40258-018-0401-y","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"19 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Both GADOLIN and the present study were funded by F. Hoffman-La Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of funding"}},{"value":"Fredrik Salvesen Haukaas, Audun Ohna and Tania Krivasi are employees of F. Hoffmann-La Roche, which markets obinutuzumab (Gazyvaro\u00ae).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of financial\/other relationships"}}]}}